Effect of clobazam as add-on antiepileptic drug in patients with epilepsy

被引:0
作者
Joshi, Rupa [1 ]
Tripathi, Manjari [2 ]
Gupta, Pooja [1 ]
Gupta, Yogendra Kumar [1 ]
机构
[1] All India Inst Med Sci, Dept Pharmacol, Adverse Drug React Monitoring Ctr, New Delhi 110029, India
[2] All India Inst Med Sci, Dept Neurol, New Delhi 110029, India
关键词
Antiepileptic drugs; clobazam; epilepsy; prescription audit; retention rate; seizures; CHILDREN; THERAPY; BENZODIAZEPINES; LAMOTRIGINE; EFFICACY;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background objectives: The use of clobazam in epilepsy has increased since its introduction in 1975. However, it has not been audited for its overall usefulness in Indian set up. The present study was aimed to evaluate usage pattern, retention rate, effectiveness and tolerability of clobazam during routine practice in an outpatient epilepsy clinic of a tertiary care hospital in New Delhi, India. Methods: This study was performed on the patients prescribed antiepileptic medication who had clobazam as last added drug in their treatment regimen during October 2010 - March 2012. These patients were followed up for two OPD visits. The primary points evaluated were retention rate, percentage of seizure-free patients and reasons for discontinuing clobazam. Results: o0 f the 417 consecutive patients, 132 (31.7%) were on clobazam treatment for more than four years (median 6 yr, range 4-15 yr). No seizure for previous 12 months was considered as seizure free and was observed in 151 (36.2%) patients. There was no improvement in seizure control in 32 (7.7%) patients. A decrease in seizure severity without any change in seizure frequency was observed in 76 (18.2%) patients. Clobazam was discontinued by 15 (3.6%) patients due to complaints like drowsiness (13), fatigue/tiredness (8), headache (6), poor memory (6), irritable behaviour (5), abdominal pain (3) and dizziness (3). Interpretation conclusions: Our results provide valuable information about the clinical use of clobazam as add-on antiepileptic drug therapy in the management of patients with epilepsy.
引用
收藏
页码:209 / 215
页数:7
相关论文
共 29 条
[1]   Revised terminology and concepts for organization of seizures and epilepsies: Report of the ILAE Commission on Classification and Terminology, 2005-2009 [J].
Berg, Anne T. ;
Berkovic, Samuel F. ;
Brodie, Martin J. ;
Buchhalter, Jeffrey ;
Cross, J. Helen ;
Boas, Walter van Emde ;
Engel, Jerome ;
French, Jacqueline ;
Glauser, Tracy A. ;
Mathern, Gary W. ;
Moshe, Solomon L. ;
Nordli, Douglas ;
Plouin, Perrine ;
Scheffer, Ingrid E. .
EPILEPSIA, 2010, 51 (04) :676-685
[2]  
Booth F, 1998, EPILEPSIA, V39, P952
[3]   Patterns of treatment response in newly diagnosed epilepsy [J].
Brodie, M. J. ;
Barry, S. J. E. ;
Bamagous, G. A. ;
Norrie, J. D. ;
Kwan, P. .
NEUROLOGY, 2012, 78 (20) :1548-1554
[4]   Clobazam in the treatment of Lennox-Gastaut syndrome [J].
Conry, Joan A. ;
Ng, Yu-Tze ;
Paolicchi, Juliann M. ;
Kernitsky, Lydia ;
Mitchell, Wendy G. ;
Ritter, Frank J. ;
Collins, Stephen D. ;
Tracy, Katherine ;
Kormany, William N. ;
Abdulnabi, Radhi ;
Riley, Bill ;
Stolle, Julie .
EPILEPSIA, 2009, 50 (05) :1158-1166
[5]   Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy [J].
da Silveira, Mariana Ribeiro Marcondes ;
Montenegro, Maria Augusta ;
Franzon, Renata Cristina ;
Guerreiro, Carlos A. M. ;
Guerreiro, Marilisa M. .
ARQUIVOS DE NEURO-PSIQUIATRIA, 2006, 64 (3B) :705-710
[6]  
DULAC O, 1983, PRESSE MED, V12, P1067
[7]   A case with Stevens Johnson syndrome triggered by combination of clobazam, lamotrigine, and valproic acid treatment [J].
Ertam, Ilgen ;
Sezgin, Aycan Ozden ;
Unal, Idil ;
Ertam, Ilgen .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2009, 48 (01) :98-99
[8]   BENZODIAZEPINES IN THE TREATMENT OF CHILDREN WITH EPILEPSY [J].
FARRELL, K .
EPILEPSIA, 1986, 27 :S45-S51
[9]  
FRECHE C, 1975, SEM HOP THERAPEUT, V51, P261
[10]   Clobazam for treatment of epilepsy [J].
Giarratano, Melissa ;
Standley, Katherine ;
Benbadis, Selim R. .
EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (02) :227-233